Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Irene Ortiz
Observed name:
I. Ortiz
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Universitat de Barcelona
Observed institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Universitat de Barcelona,
Institut Curie
ORCID:
0000-0001-6736-8617
Observed ORCID:
0000-0001-6736-8617
OpenAlex ID:
A5027862631
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
·
Clinical Cancer Research
·
23
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Data from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.
2025
·
Laia Fernandez-Mañas
, Irene Ortiz
, et al.
·
Journal of Clinical Oncology
PDF
EP-2354: Impact of PET-TC-simulation in radiotherapy treatment planning in nasopharyngeal carcinoma
2018
·
R. Roncero
, J. Pardo
, et al.
·
Radiotherapy and Oncology
Show more works
View as search
Works count:
22
Citation count:
23
H-index:
1
I10-index:
1
Year
Topic
Type